サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1447720

HER2+胃癌市場の評価：治療タイプ・ステージ・エンドユーザー・地域別の機会および予測 (2017～2031年)

HER2+ Gastric Cancer Market Assessment, By Therapy Type, By Stage, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日
ページ情報
英文 232 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
HER2+胃癌市場の評価：治療タイプ・ステージ・エンドユーザー・地域別の機会および予測 (2017～2031年)
出版日: 2024年03月11日
発行: Market Xcel - Markets and Data
ページ情報: 英文 232 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のHER2+胃癌の市場規模は、2023年の13億450万米ドルから、2024年から2031年の予測期間中は3.37%のCAGRで推移し、2031年には17億59万米ドルの規模に成長すると予測されています。

HER2+胃癌の市場は、胃癌の症例数の増加により成長しています。これらの症例の増加はあらゆる年齢層で見られます。技術の進歩、R&Dへの投資の増加、政府のイニシアチブも市場を活性化しています。胃癌の有病率は世界で急速に増加しており、さまざまな種類の癌のほぼ5％を占めています。市場は、より短時間で高精度に癌を診断できるソリューションの面で技術的進歩を経験しています。製薬メーカーは、より効果的で患者の身体に適合する薬剤を開発しています。

胃癌の有病率の増加

胃癌の有病率は急速に増加しています。この疾患の有病率上昇には、ライフスタイルや食習慣の変化、人口動態的要因などさまざまな理由が考えられます。このタイプの胃癌は分子レベルで他のタイプと異なるため、標的療法によって異なる治療を行う必要があります。胃癌の有病率があらゆる年齢層、特に高齢者において上昇し続けているため、効果的な治療法や革新的な治療アプローチに対する需要も高まっています。この課題には、高度な診断法を開発することで早期発見に重点を置き、人々に病気に対する認識を広め、定期的な健康診断を受けることの重要性を伝えることで対処する必要があります。

技術の進歩

診断技術の進歩も市場に大きな影響を与えています。これらの進歩は、胃癌の同定、治療、モニタリングに革命をもたらし、最終的に患者の予後に利益をもたらします。高精細画像による内視鏡検査などの最新の診断技術は、胃粘膜の正確な可視化を可能にし、早期段階での異常や病変の発見を可能にします。正確な病期分類と病勢進行のモニタリングは、磁気共鳴画像法 (MRI) や陽電子放射断層撮影法 (PET) のような高度な画像診断法によって可能となります。分子バイオマーカー解析は、胃癌に関連する特定の遺伝子や分子の変化を検出することで、診断の分野に変革をもたらしつつあります。この方法は、リスク評価、早期発見、治療効果予測に役立ちます。

機械学習とAIの統合も診断精度を向上させています。大規模なデータセットをAlアルゴリズムで分析し、胃癌を指し示す小さなパターンや特徴を見つけることができます。これにより、より早く、より正確な診断が可能になります。遠隔医療やデジタルヘルスソリューションへの世界のシフトにより、特に医療インフラが脆弱な地域では、専門家のアドバイスやセカンドオピニオン、遠隔診察へのアクセスが容易になりつつあります。これらの開発により、胃癌の早期発見が可能になり、医師は十分な情報に基づいた治療方針の決定に必要な情報を得ることができ、オーダーメイドの治療法の確立がサポートされます。

当レポートでは、世界のHER2+胃癌の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、規制の枠組み、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界のHER2+胃癌市場の展望

  • 市場規模・予測
  • 治療タイプ別
    • 化学療法
    • 免疫療法
    • 放射線療法
    • 標的療法
    • その他
  • ステージ別
    • ステージI
    • ステージII
    • ステージⅢ
    • ステージIV
  • エンドユーザー別
    • 病院
    • 専門クリニック
    • 外来手術センター
    • その他
  • 地域別
    • 北米
    • 欧州
    • 南米
    • アジア太平洋
    • 中東・アフリカ
  • 企業別の市場シェア

第5章 世界のHER2+胃癌市場の展望：地域別

  • 北米
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ

第6章 市場マッピング

  • 治療タイプ別
  • ステージ別
  • エンドユーザー別
  • 地域別

第7章 マクロ環境と産業構造

  • 需給分析
  • 輸出入分析
  • バリューチェーン分析
  • PESTEL分析
  • ポーターのファイブフォース分析

第8章 市場力学

  • 成長促進要因
  • 成長阻害要因 (課題・抑制要因)

第9章 規制の枠組みとイノベーション

  • 臨床試験
  • 特許の情勢
  • 規制当局の承認
  • イノベーション/新興技術

第10章 主要企業の情勢

  • 市場リーダー上位5社の競合マトリックス
  • 市場リーダー上位5社の市場収益分析
  • M&A・ジョイントベンチャー (該当する場合)
  • SWOT分析 (主要企業)
  • 特許分析 (該当する場合)

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

  • 市場リーダー上位5社の競合マトリックス
  • 市場リーダー上位5社の市場収益分析 (%、2023年)
  • 合併および買収/合弁事業 (該当する場合)
  • SWOT分析 (市場参入企業5名向け)
  • 特許分析 (該当する場合)

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb
  • Ono Pharmaceutical Co. Ltd
  • Hutchison Medipharma
  • LintonPharm Ltd
  • Shanghai Henlius Biotech Inc
  • Sanofi S A
  • Pfizer Inc.
  • Novartis AG
  • Abott Inc.

第14章 戦略的提言

第15章 当社について・免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 2.Global HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 3.Global HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 4.Global HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 5.Global HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 6.Global HER2+ Gastric Cancer Market Share (%), By Region, 2017-2031F
  • Figure 7.North America HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 8.North America HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 9.North America HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 10.North America HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 11.North America HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 12.North America HER2+ Gastric Cancer Market Share (%), By Country, 2017-2031F
  • Figure 13.United States HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 14.United States HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 15.United States HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 16.United States HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 17.United States HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 18.Canada HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 19.Canada HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 20.Canada HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 21.Canada HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 22.Canada HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 23.Mexico HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 24.Mexico HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 25.Mexico HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 26.Mexico HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 27.Mexico HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 28.Europe HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 29.Europe HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 30.Europe HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 31.Europe HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 32.Europe HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 33.Europe HER2+ Gastric Cancer Market Share (%), By Country, 2017-2031F
  • Figure 34.Germany HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 35.Germany HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 36.Germany HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 37.Germany HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 38.Germany HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 39.France HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 40.France HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 41.France HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 42.France HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 43.France HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 44.Italy HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 45.Italy HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 46.Italy HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 47.Italy HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 48.Italy HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 49.United Kingdom HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 50.United Kingdom HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 51.United Kingdom HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 52.United Kingdom HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 53.United Kingdom HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 54.Russia HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 55.Russia HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 56.Russia HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 57.Russia HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 58.Russia HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 59.Netherlands HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 60.Netherlands HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 61.Netherlands HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 62.Netherlands HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 63.Netherlands HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 64.Spain HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 65.Spain HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 66.Spain HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 67.Spain HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 68.Spain HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 69.Turkey HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 70.Turkey HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 71.Turkey HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 72.Turkey HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 73.Turkey HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 74.Poland HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 75.Poland HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 76.Poland HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 77.Poland HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 78.Poland HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 79.South America HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 80.South America HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 81.South America HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 82.South America HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 83.South America HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 84.South America HER2+ Gastric Cancer Market Share (%), By Country, 2017-2031F
  • Figure 85.Brazil HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 86.Brazil HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 87.Brazil HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 88.Brazil HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 89.Brazil HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 90.Argentina HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 91.Argentina HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 92.Argentina HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 93.Argentina HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 94.Argentina HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 95.Asia-Pacific HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 96.Asia-Pacific HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 97.Asia-Pacific HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 98.Asia-Pacific HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 99.Asia-Pacific HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 100.Asia-Pacific HER2+ Gastric Cancer Market Share (%), By Country, 2017-2031F
  • Figure 101.India HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 102.India HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 103.India HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 104.India HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 105.India HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 106.China HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 107.China HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 108.China HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 109.China HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 110.China HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 111.Japan HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 112.Japan HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 113.Japan HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 114.Japan HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 115.Japan HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 116.Australia HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 117.Australia HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 118.Australia HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 119.Australia HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 120.Australia HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 121.Vietnam HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 122.Vietnam HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 123.Vietnam HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 124.Vietnam HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 125.Vietnam HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 126.South Korea HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 127.South Korea HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 128.South Korea HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 129.South Korea HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 130.South Korea HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 131.Indonesia HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 132.Indonesia HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 133.Indonesia HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 134.Indonesia HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 135.Indonesia HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 136.Philippines HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 137.Philippines HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 138.Philippines HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 139.Philippines HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 140.Philippines HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 141.Middle East & Africa HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 142.Middle East & Africa HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 143.Middle East & Africa HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 144.Middle East & Africa HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 145.Middle East & Africa HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 146.Middle East & Africa HER2+ Gastric Cancer Market Share (%), By Country, 2017-2031F
  • Figure 147.Saudi Arabia HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 148.Saudi Arabia HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 149.Saudi Arabia HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 150.Saudi Arabia HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 151.Saudi Arabia HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 152.UAE HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 153.UAE HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 154.UAE HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 155.UAE HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 156.UAE HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 157.South Africa HER2+ Gastric Cancer Market, By Value, in USD Million, 2017-2031F
  • Figure 158.South Africa HER2+ Gastric Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 159.South Africa HER2+ Gastric Cancer Market Share (%), By Therapy Type, 2017-2031F
  • Figure 160.South Africa HER2+ Gastric Cancer Market Share (%), By Stage, 2017-2031F
  • Figure 161.South Africa HER2+ Gastric Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 162.By Therapy Type Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 163.By Stage Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 164.By End-user Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 165.By Region Map-Market Size (USD Million) & Growth Rate (%), 2023
目次
Product Code: MX11127

Global HER2+ gastric cancer market is projected to witness a CAGR of 3.37% during the forecast period 2024-2031, growing from USD 1304.5 million in 2023 to USD 1700.59 million in 2031. Globally, gastric cancer ranks third in terms of cancer-related deaths and is the sixth most frequent type of cancer. Although there are no symptoms associated with early stomach cancer, some people receive confirmation about the cancer once they are diagnosed. A growth-promoting protein called HER2 is overexpressed on the surface of stomach cancer cells and treatment for these cancers often involves the use of drugs that specifically target the HER2 protein.

The HER2+ gastric cancer market is experiencing growth due to rising numbers of stomach cancer cases. The rise in these cases is seen across all the ages. Technological advancements, increasing investments in R&D, along with governments initiatives are also fueling the market. The prevalence of stomach cancer is increasing at a rapid rate globally, making it almost 5% of all different types of cancer. The market is experiencing technological advancements in terms of solutions that are capable of diagnosing cancer with less time and high accuracy. Pharmaceutical manufacturers are developing drugs that are more effective and compatible with patient's body.

In February 2022, Prime Research Institute and Ono Pharmaceuticals Co., along with Bristol-Myers Squibb, entered a contractual based collaboration to start a large scale, industry sponsored, clinical investigation involving patients with gastric cancer who were undergoing a treatment with Opdivo in combination with chemotherapy. "CyberOncology". It is a data input system developed by PRiMER-R that standardizes, organizes, manages, and integrates real-world data collected from routine cancer clinical practices.

Increasing Prevalence of Gastric Cancer

The prevalence of gastric cancer is rising at a rapid pace. There may be various reasons for the rising prevalence of this disease such as changing lifestyles, dietary habits, and population and demographics. However, what triggers it in the body may be over-expression or over-proliferation of HER2 protein that is present in the body. This form of gastric cancer is different from other types on a molecular level, due to which it is required to be treated differently through targeted therapies. As the prevalence of gastric cancer continues to rise in all age groups, especially the elderly, the demand for effective therapies and innovative treatment approaches also grows. This challenge needs to be addressed by emphasizing more on early detection by developing advanced diagnostic methods, spreading awareness to people about the disease, and communicating the importance of getting regular health checkups. According to a recent study published by ICMR, the number of Indians suffering from cancer is expected to grow to 29.8 million in the year 2025, from 26.7 million in 2021. Accordingly, talking about the burden of cancers in India, seven cancer types account for more than 40% of the total disease burden, whereas gastric cancer itself accounts for 5.2% alone.

Advancements in Technology

Technological advancements made for diagnosis have been playing a major role in influencing the global market for gastric cancer therapy. These developments are revolutionizing the identification, treatment, and monitoring of stomach cancer, which will ultimately benefit patients' prognosis. Modern diagnostic techniques, such as endoscopy with high-definition imaging, enable precise visualization of the stomach lining and detection of anomalies and lesions in their early stages. Accurate staging and disease progression monitoring are made possible by advanced imaging modalities like magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. Molecular biomarker analysis is transforming the field of diagnosis by detecting particular genetic and molecular changes linked to stomach cancer. This method helps with risk assessment, early detection, and treatment response prediction.

Integration of machine learning and artificial intelligence (AI) improves diagnostic precision. Large datasets may be analyzed by Al algorithms, which can then be used to find small patterns and traits that point to stomach cancer. This allows for earlier and more accurate diagnosis. Access to expert advice, second opinions, and remote consultations is becoming easier due to the global shift towards telemedicine and digital health solutions, especially in areas with weak healthcare infrastructure. These developments enable early detection of stomach cancer, provide doctors with the information they need to make well-informed treatment decisions and support the creation of tailored therapeutic methods.

In September 2022, Henlius' HLX22, an anti-human epidermal growth factor receptor-2 (HER2) humanized monoclonal antibody (mAb) injection, underwent a phase 1 clinical trial in patients with advanced solid tumors overexpressing HER2. The study's findings proved that HLX22 is safe and clinically effective.

Immunotherapies are Dominating the Market

Immunotherapy utilizes the body's immune system to recognize and eliminate cancer cells. Treatment options for gastric cancer are limited but immunotherapy has emerged as a clinically advanced alternative. Immune checkpoint inhibitors are a part of immunotherapies that have gained traction over the past few years. Checkpoint proteins like PD-1, PD-L1 and CTLA-4, which are exploited by the cancer cells to evade the immune response, are targeted by these drugs. The immune checkpoint inhibitors block these proteins and hence enable the immune system to build a strong attack against cancer. There have been times when patients who stopped responding to any other therapies have shown great results after going through immunotherapy. It also gives an experience of prolonged survival and a better quality of life. Combining immunotherapy with other therapies like targeted therapy and chemotherapy has proven to be of maximum effectiveness with the potential to stimulate long-lasting immune responses. The dominance of Immunotherapy flags a shift in this market, enabling rapid evolution of the market.

For instance, stage 1 of the worldwide phase III trial enrollment was completed in January 2022 by LintonPharm Co., Ltd., a biopharmaceutical firm based in China that specializes in the development of T cell-engaging bispecific antibodies for cancer immunotherapy. In this experiment, adult patients with advanced gastric cancer and peritonitis were assessed for safety and effectiveness with a bispecific monoclonal antibody called catumaxomab (GCPC).

North America to Dominate Gastric Cancer Market

Countries from North America, such as the United States, Canada, and Mexico, are contributing to market expansion due to the prevalence of gastric cancer, the availability of advanced healthcare infrastructure, the availability of healthcare professionals, and high healthcare expenditure. There is a significant burden of gastric cancer in North America, with millions of new cases being reported each year. The availability of advanced technologies, drugs, and diagnostics that give results faster and with more precision, modern infrastructure, vaccinations, and all the possible treatment options have created a very favorable environment for the development and expansion of this market in North America. Moreover, with the presence of many leading biopharmaceuticals in the region that have a strong and established pipeline of HER2+ gastric cancer treatments, the region is prone to market expansion with continued investment from the government and pharmaceutical companies.

According to statistics published in 2024 by the American Cancer Society for stomach cancer in the United States, there are about 26,890 new cases of gastric cancer, out of which 16,160 were recorded in men and 10,730 in women. There are about 10,880 deaths associated with this type of cancer. Out of which 6490 are men and 4390 are women. Stomach cancer accounts for about 1.5% of all new cancers diagnosed in the US, each year.

Future Market Scenario (2024 - 2031F)

The market for HER2+ gastric cancer is anticipated to further rise as people are becoming aware of the molecular subtypes of cancer. Future developments in this market are expected to be influenced by improvements in diagnostics and newly available treatment options, specifically combination therapy. Industry players must continue to collaborate and comply with changing regulatory standards to improve patient outcomes. Since this market has the potential to revolutionize the way illness is treated, if research and development efforts are sustainable, it can provide patients with a better quality of life. Partnerships and collaborations among pharmaceutical companies, healthcare providers, and patient advocacy groups are critical to meet the changing demands of patients with gastric cancer.

For example, in April 2022, BDR Pharmaceuticals introduced a drug called Furmecil, which is an oral generic medicine developed to treat patients with advanced gastric cancer. It is known to be the combination of three drugs - Tegafur, Gimeracil, and Oteracil. This combination has shown to be highly effective and safe as suggested by the BDR Pharmaceuticals itself.

Key Players Landscape and Outlook

There are several key players in the global HER2+ gastric cancer market. Currently, many competitors control most of the market. Among the businesses that are currently governing the market shares are AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd, Hutchison Medipharma, LintonPharm Ltd, Shanghai Henlius Biotech Inc, Sanofi S A, Pfizer Inc., Novartis AG, Abott Inc., etc. These companies are leading the market share due to their continuous efforts toward R&D, technological advancements, and drug development that is effective and reliable.

In November 2023, Alphamab Oncology and CSPC Pharmaceutical Group Co. Ltd jointly stated that a breakthrough therapy designation was granted to a HER2 specific antibody (KN026) combined with chemotherapy for treating gastric cancer and gastroesophageal junction cancer.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global HER2+ Gastric Cancer Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1.By Value
    • 4.1.2.By Volume
  • 4.2.By Therapy Type
    • 4.2.1.Chemotherapy
    • 4.2.2.Immunotherapy
    • 4.2.3.Radiation Therapy
    • 4.2.4.Targeted Therapy
    • 4.2.5.Others
  • 4.3.By Stage
    • 4.3.1.Stage I
    • 4.3.2.Stage II
    • 4.3.3.Stage III
    • 4.3.4.Stage IV
  • 4.4.By End-user
    • 4.4.1.Hospitals
    • 4.4.2.Specialty Clinics
    • 4.4.3.Ambulatory Surgical Center
    • 4.4.4.Others
  • 4.5.By Region
    • 4.5.1.North America
    • 4.5.2.Europe
    • 4.5.3.Asia-Pacific
    • 4.5.4.South End-user America
    • 4.5.5.Middle East and Africa
  • 4.6.By Company Market Share (%), 2023

5.Global HER2+ Gastric Cancer Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Therapy Type
      • 5.1.2.1.Chemotherapy
      • 5.1.2.2.Immunotherapy
      • 5.1.2.3.Radiation Therapy
      • 5.1.2.4.Targeted Therapy
      • 5.1.2.5.Others
    • 5.1.3.By Stage
      • 5.1.3.1.Stage I
      • 5.1.3.2.Stage II
      • 5.1.3.3.Stage III
      • 5.1.3.4.Stage IV
    • 5.1.4.By End-user
      • 5.1.4.1.Hospitals
      • 5.1.4.2.Specialty Clinics
      • 5.1.4.3.Ambulatory Surgical Center
      • 5.1.4.4.Others
    • 5.1.5.United States*
      • 5.1.5.1.Market Size & Forecast
      • 5.1.5.1.1.By Value
      • 5.1.5.1.2.By Volume
      • 5.1.5.2.By Therapy Type
      • 5.1.5.2.1.Chemotherapy
      • 5.1.5.2.2.Immunotherapy
      • 5.1.5.2.3.Radiation Therapy
      • 5.1.5.2.4.Targeted Therapy
      • 5.1.5.2.5.Others
      • 5.1.5.3.By Stage
      • 5.1.5.3.1.Stage I
      • 5.1.5.3.2.Stage II
      • 5.1.5.3.3.Stage III
      • 5.1.5.3.4.Stage IV
      • 5.1.5.4.By End-user
      • 5.1.5.4.1.Hospitals
      • 5.1.5.4.2.Specialty Clinics
      • 5.1.5.4.3.Ambulatory Surgical Center
      • 5.1.5.4.4.Others
    • 5.1.6.Canada
    • 5.1.7.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1.Germany
    • 5.2.2.France
    • 5.2.3.Italy
    • 5.2.4.United Kingdom
    • 5.2.5.Russia
    • 5.2.6.Netherlands
    • 5.2.7.Spain
    • 5.2.8.Turkey
    • 5.2.9.Poland
  • 5.3.Asia-Pacific
    • 5.3.1.India
    • 5.3.2.China
    • 5.3.3.Japan
    • 5.3.4.Australia
    • 5.3.5.Vietnam
    • 5.3.6.South Korea
    • 5.3.7.Indonesia
    • 5.3.8.Philippines
  • 5.4.South America
    • 5.4.1.Brazil
    • 5.4.2.Argentina
  • 5.5.Middle East & Africa
    • 5.5.1.Saudi Arabia
    • 5.5.2.UAE
    • 5.5.3.South Africa

6.Market Mapping, 2023

  • 6.1.By Therapy Type
  • 6.2.By Stage
  • 6.3.By End-user
  • 6.4.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.5.1.Supplier Power
    • 7.5.2.Buyer Power
    • 7.5.3.Substitution Threat
    • 7.5.4.Threat from New Entrant
    • 7.5.5.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Clinical Trials
  • 9.2.Patent Landscape
  • 9.3.Regulatory Approvals
  • 9.4.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)
  • 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.AstraZeneca PLC
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.Bayer AG
  • 13.3.Bristol-Myers Squibb
  • 13.4.Ono Pharmaceutical Co. Ltd
  • 13.5.Hutchison Medipharma
  • 13.6.LintonPharm Ltd
  • 13.7.Shanghai Henlius Biotech Inc
  • 13.8.Sanofi S A
  • 13.9.Pfizer Inc.
  • 13.10.Novartis AG
  • 13.11.Abott Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer